Exhibit 99.2
Royalty Revenue by Product ($ in 000's) *
Avastin | Q1 | Q2 | Q3 | Q4 | Total | |||||||||||||||
2011 | 22,283 | 41,967 | - | - | 64,250 | |||||||||||||||
2010 | 16,870 | 44,765 | 29,989 | 24,922 | 116,547 | |||||||||||||||
2009 | 13,605 | 35,161 | 21,060 | 15,141 | 84,966 | |||||||||||||||
2008 | 9,957 | 30,480 | 19,574 | 12,394 | 72,405 | |||||||||||||||
2007 | 8,990 | 21,842 | 17,478 | 9,549 | 57,859 | |||||||||||||||
2006 | 10,438 | 15,572 | 15,405 | 12,536 | 53,952 |
Herceptin | Q1 | Q2 | Q3 | Q4 | Total | |||||||||||||||
2011 | 25,089 | 42,209 | - | - | 67,298 | |||||||||||||||
2010 | 23,402 | 38,555 | 27,952 | 25,441 | 115,350 | |||||||||||||||
2009 | 16,003 | 32,331 | 26,830 | 18,615 | 93,779 | |||||||||||||||
2008 | 14,092 | 34,383 | 28,122 | 20,282 | 96,880 | |||||||||||||||
2007 | 19,035 | 28,188 | 22,582 | 14,802 | 84,608 | |||||||||||||||
2006 | 15,142 | 19,716 | 21,557 | 20,354 | 76,769 |
Lucentis | Q1 | Q2 | Q3 | Q4 | Total | |||||||||||||||
2011 | 8,878 | 24,313 | - | - | 33,191 | |||||||||||||||
2010 | 7,220 | 19,091 | 10,841 | 8,047 | 45,198 | |||||||||||||||
2009 | 4,621 | 12,863 | 8,123 | 6,152 | 31,759 | |||||||||||||||
2008 | 3,636 | 11,060 | 7,631 | 4,549 | 26,876 | |||||||||||||||
2007 | 2,931 | 6,543 | 6,579 | 3,517 | 19,570 | |||||||||||||||
2006 | - | - | 289 | 3,335 | 3,624 |
Xolair | Q1 | Q2 | Q3 | Q4 | Total | |||||||||||||||
2011 | 4,590 | 7,621 | - | - | 12,211 | |||||||||||||||
2010 | 3,723 | 6,386 | 4,980 | 4,652 | 19,741 | |||||||||||||||
2009 | 2,665 | 5,082 | 4,085 | 3,722 | 15,553 | |||||||||||||||
2008 | 1,488 | 4,866 | 3,569 | 2,927 | 12,850 | |||||||||||||||
2007 | 1,684 | 3,942 | 3,332 | 2,184 | 11,142 | |||||||||||||||
2006 | 2,263 | 2,969 | 3,041 | 2,495 | 10,768 |
Tysabri | Q1 | Q2 | Q3 | Q4 | Total | |||||||||||||||
2011 | 9,891 | 10,796 | - | - | 20,687 | |||||||||||||||
2010 | 8,791 | 8,788 | 8,735 | 9,440 | 35,754 | |||||||||||||||
2009 | 6,656 | 7,050 | 7,642 | 8,564 | 29,912 | |||||||||||||||
2008 | 3,883 | 5,042 | 5,949 | 6,992 | 21,866 | |||||||||||||||
2007 | 839 | 1,611 | 2,084 | 2,836 | 7,370 | |||||||||||||||
2006 | - | - | - | 237 | 237 |
* As reported to PDL by its licensees
Reported Net Sales Revenue by Product ($ in 000's) *
Avastin | Q1 | Q2 | Q3 | Q4 | Total | |||||||||||||||
2011 | 1,597,461 | 1,582,705 | - | - | 3,180,166 | |||||||||||||||
2010 | 1,506,788 | 1,596,892 | 1,594,707 | 1,646,218 | 6,344,605 | |||||||||||||||
2009 | 1,345,487 | 1,295,536 | 1,439,730 | 1,514,053 | 5,594,806 | |||||||||||||||
2008 | 980,715 | 1,084,930 | 1,180,427 | 1,239,382 | 4,485,454 | |||||||||||||||
2007 | 678,068 | 746,587 | 797,013 | 875,084 | 3,096,752 | |||||||||||||||
2006 | 439,318 | 516,052 | 570,551 | 592,897 | 2,118,817 |
Herceptin | Q1 | Q2 | Q3 | Q4 | Total | |||||||||||||||
2011 | 1,391,568 | 1,559,975 | - | - | 2,951,543 | |||||||||||||||
2010 | 1,270,846 | 1,349,512 | 1,300,934 | 1,409,310 | 5,330,602 | |||||||||||||||
2009 | 1,210,268 | 1,133,993 | 1,226,435 | 1,278,626 | 4,849,323 | |||||||||||||||
2008 | 1,105,426 | 1,195,215 | 1,211,982 | 1,186,806 | 4,699,428 | |||||||||||||||
2007 | 891,761 | 949,556 | 979,602 | 1,015,033 | 3,835,952 | |||||||||||||||
2006 | 529,585 | 659,719 | 761,099 | 803,576 | 2,753,979 |
Lucentis | Q1 | Q2 | Q3 | Q4 | Total | |||||||||||||||
2011 | 887,757 | 943,418 | - | - | 1,831,175 | |||||||||||||||
2010 | 721,967 | 698,890 | 745,376 | 804,684 | 2,970,917 | |||||||||||||||
2009 | 462,103 | 469,736 | 555,296 | 615,212 | 2,102,347 | |||||||||||||||
2008 | 363,615 | 393,682 | 460,167 | 454,922 | 1,672,386 | |||||||||||||||
2007 | 224,820 | 219,579 | 299,995 | 322,300 | 1,066,695 | |||||||||||||||
2006 | - | - | 10,689 | 157,742 | 168,431 |
Xolair | Q1 | Q2 | Q3 | Q4 | Total | |||||||||||||||
2011 | 267,754 | 277,642 | - | - | 545,396 | |||||||||||||||
2010 | 228,859 | 225,878 | 251,055 | 263,389 | 969,179 | |||||||||||||||
2009 | 184,669 | 181,086 | 211,006 | 219,693 | 796,454 | |||||||||||||||
2008 | 137,875 | 169,521 | 177,179 | 183,753 | 668,329 | |||||||||||||||
2007 | 129,172 | 130,700 | 144,250 | 147,754 | 551,876 | |||||||||||||||
2006 | 95,241 | 99,354 | 112,608 | 118,002 | 425,204 |
Tysabri | Q1 | Q2 | Q3 | Q4 | Total | |||||||||||||||
2011 | 329,696 | 356,876 | - | - | 686,572 | |||||||||||||||
2010 | 293,047 | 287,925 | 293,664 | 316,657 | 1,191,292 | |||||||||||||||
2009 | 221,854 | 229,993 | 257,240 | 285,481 | 994,569 | |||||||||||||||
2008 | 129,430 | 163,076 | 200,783 | 233,070 | 726,359 | |||||||||||||||
2007 | 30,468 | 48,715 | 71,972 | 94,521 | 245,675 | |||||||||||||||
2006 | - | - | - | 7,890 | 7,890 |
* As reported to PDL by its licensees
Avastin Sales | 2010 - Q1 | 2010 - Q2 | 2010 - Q3 | 2010 - Q4 | 2011 - Q1 | 2011 - Q2 | ||||||||||||||||||
US Made & Sold | 755,680 | 814,872 | 820,453 | 800,139 | 708,539 | 719,967 | ||||||||||||||||||
US Made & ex-US Sold | 668,478 | 355,742 | 338,929 | 415,576 | 580,981 | 548,710 | ||||||||||||||||||
ex-US Made & Sold | 82,630 | 426,277 | 435,325 | 430,503 | 307,941 | 314,028 | ||||||||||||||||||
Total | 1,506,788 | 1,596,892 | 1,594,707 | 1,646,218 | 1,597,461 | 1,582,705 | ||||||||||||||||||
US Made & Sold | 50 | % | 51 | % | 51 | % | 49 | % | 44 | % | 45 | % | ||||||||||||
US Made & ex-US Sold | 44 | % | 22 | % | 21 | % | 25 | % | 36 | % | 35 | % | ||||||||||||
ex-US Made & Sold | 5 | % | 27 | % | 27 | % | 26 | % | 19 | % | 20 | % |
Herceptin Sales | 2010 - Q1 | 2010 - Q2 | 2010 - Q3 | 2010 - Q4 | 2011 - Q1 | 2011 - Q2 | ||||||||||||||||||
US Made & Sold | 375,139 | 406,222 | 410,563 | 416,611 | 409,854 | 442,903 | ||||||||||||||||||
US Made & ex-US Sold | 353,539 | 312,792 | 306,085 | 425,303 | 423,053 | 642,670 | ||||||||||||||||||
ex-US Made & Sold | 542,168 | 630,498 | 584,286 | 567,396 | 558,661 | 474,402 | ||||||||||||||||||
Total | 1,270,846 | 1,349,512 | 1,300,934 | 1,409,310 | 1,391,568 | 1,559,975 | ||||||||||||||||||
US Made & Sold | 30 | % | 30 | % | 32 | % | 30 | % | 29 | % | 28 | % | ||||||||||||
US Made & ex-US Sold | 28 | % | 23 | % | 24 | % | 30 | % | 30 | % | 41 | % | ||||||||||||
ex-US Made & Sold | 43 | % | 47 | % | 45 | % | 40 | % | 40 | % | 30 | % |
Lucentis Sales | 2010 - Q1 | 2010 - Q2 | 2010 - Q3 | 2010 - Q4 | 2011 - Q1 | 2011 - Q2 | ||||||||||||||||||
US Made & Sold | 306,995 | 300,501 | 326,840 | 360,911 | 378,451 | 409,674 | ||||||||||||||||||
US Made & ex-US Sold | 414,972 | 398,389 | 418,536 | 443,773 | 509,307 | 533,745 | ||||||||||||||||||
ex-US Made & Sold | - | - | - | - | - | - | ||||||||||||||||||
Total | 721,967 | 698,890 | 745,376 | 804,684 | 887,757 | 943,418 | ||||||||||||||||||
US Made & Sold | 43 | % | 43 | % | 44 | % | 45 | % | 43 | % | 43 | % | ||||||||||||
US Made & ex-US Sold | 57 | % | 57 | % | 56 | % | 55 | % | 57 | % | 57 | % | ||||||||||||
ex-US Made & Sold | 0 | % | 0 | % | 0 | % | 0 | % | 0 | % | 0 | % |
Xolair Sales | 2010 - Q1 | 2010 - Q2 | 2010 - Q3 | 2010 - Q4 | 2011 - Q1 | 2011 - Q2 | ||||||||||||||||||
US Made & Sold | 149,628 | 145,245 | 165,109 | 170,001 | 164,621 | 167,608 | ||||||||||||||||||
US Made & ex-US Sold | - | - | - | - | - | - | ||||||||||||||||||
ex-US Made & Sold | 79,231 | 80,632 | 85,945 | 93,388 | 103,133 | 110,034 | ||||||||||||||||||
Total | 228,859 | 225,878 | 251,055 | 263,389 | 267,754 | 277,642 | ||||||||||||||||||
US Made & Sold | 65 | % | 64 | % | 66 | % | 65 | % | 61 | % | 60 | % | ||||||||||||
US Made & ex-US Sold | 0 | % | 0 | % | 0 | % | 0 | % | 0 | % | 0 | % | ||||||||||||
ex-US Made & Sold | 35 | % | 36 | % | 34 | % | 35 | % | 39 | % | 40 | % |
Total Sales | 2010 - Q1 | 2010 - Q2 | 2010 - Q3 | 2010 - Q4 | 2011 - Q1 | 2011 - Q2 | ||||||||||||||||||
US Made & Sold | 1,587,442 | 1,666,840 | 1,722,965 | 1,747,662 | 1,661,465 | 1,740,152 | ||||||||||||||||||
US Made & ex-US Sold | 1,436,989 | 1,081,147 | 1,063,551 | 1,284,652 | 1,513,340 | 1,725,125 | ||||||||||||||||||
ex-US Made & Sold | 704,029 | 1,137,407 | 1,105,556 | 1,091,287 | 969,735 | 898,464 | ||||||||||||||||||
Total | 3,728,460 | 3,885,394 | 3,892,072 | 4,123,601 | 4,144,540 | 4,363,741 | ||||||||||||||||||
US Made & Sold | 43 | % | 43 | % | 44 | % | 42 | % | 40 | % | 40 | % | ||||||||||||
US Made & ex-US Sold | 39 | % | 28 | % | 27 | % | 31 | % | 37 | % | 40 | % | ||||||||||||
ex-US Made & Sold | 19 | % | 29 | % | 28 | % | 26 | % | 23 | % | 21 | % |
* As reported to PDL by its licensees